“…Recent research largely illustrates that the in vitro and in vivo properties of ruthenium compounds can be finely tuned by ligand variation. Intense investigations converge on ligand selection from the arene, phosphine, aromatic heterocycles, pyridine, pta, pybox, pyrazolone-based β-ketoamine, nitrosyl, Schiff-base, carboxamide, carbothioamide, thiourea, thiocarbamate, thiosemicarbazone, and hydrazone classes [36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78]. Innovations were applied to construct coordination-driven self-assembled arene-Ru metalla-rectangles endowed with stronger cytotoxicity against all cancer cell lines and even more effective than established anticancer drugs like doxorubicin and cisplatin [50].…”